Basic Information
| LncRNA/CircRNA Name | circ_0020123 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, luciferase reporter assay, Microarray, other |
| Sample | NSCLC tissues and cell lines (PC9, H1573,A549, SK-MES-1, H1299, and Calu-3) |
| Expression Pattern | up-regulated |
| Function Description | Moreover, up-regulation of hsa_circ_0020123 was recognized to be closely associated with a poor differentiation degree, lymph node metastasis, a high TNM stage and dismal prognosis for NSCLC patients. Typically, knockdown of hsa_circ_0020123 could inhibit the NSCLC growth and metastasis both in vitro and in vivo, which could be reversed by the hsa_circ_0020123 overexpression. Importantly, miR-144 was identified as the hsa_circ_0020123-associated miRNA through performing RNA in vivo precipitation (RIP) in NSCLC cells using a biotin-labeled hsa_circ_0020123 probe. Besides, our results suggested that, miR-144 suppression had determined the oncogenic properties mediated by hsa_circ_0020123. In addition, hsa_circ_0020123 could upregulate ZEB1 and EZH2 through competitively binding with miR-144. Finally, the administration of hsa_circ_0020123 siRNA could suppress the growth and metastasis in NSCLC-bearing mice in vivo. |
| Pubmed ID | 30210911 |
| Year | 2018 |
| Title | A Novel Circular RNA hsa_circ_0020123 Exerts Oncogenic Properties Through Suppression of miR-144 in Non-Small Cell Lung Cancer |
External Links
| Links for circ_0020123 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |